IDEAYA Biosciences Appoints New Chief Medical Officer

TL;DR

IDEAYA lands oncology vet Smith as CMO to push pipeline forward.

AI Summary

On July 8, 2024, IDEAYA Biosciences, Inc. announced the appointment of Dr. S. Mark Smith as Chief Medical Officer. Dr. Smith brings extensive experience in oncology drug development, having previously held leadership roles at companies like Genentech and Exelixis. His appointment is expected to bolster IDEAYA's clinical development strategy for its pipeline of precision oncology therapies.

Why It Matters

The appointment of a seasoned Chief Medical Officer like Dr. Smith is crucial for advancing IDEAYA's promising oncology drug candidates through clinical trials and towards potential market approval.

Risk Assessment

Risk Level: medium — The appointment of a new CMO is a significant leadership change that could impact the company's strategic direction and execution of clinical trials.

Key Players & Entities

• IDEAYA Biosciences, Inc. (company) — Registrant
• Dr. S. Mark Smith (person) — Newly appointed Chief Medical Officer
• Genentech (company) — Previous employer of Dr. Smith
• Exelixis (company) — Previous employer of Dr. Smith
• July 8, 2024 (date) — Date of report and earliest event

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share IDYA The Nasdaq

Filing Documents

• d587447d8k.htm (8-K) — 30KB
• 0001193125-24-175867.txt ( ) — 152KB
• idya-20240708.xsd (EX-101.SCH) — 3KB
• idya-20240708_lab.xml (EX-101.LAB) — 18KB
• idya-20240708_pre.xml (EX-101.PRE) — 11KB
• d587447d8k_htm.xml (XML) — 4KB

Forward-Looking Statements

Forward-Looking Statements Certain statements contained herein are forward-looking statements including, but not limited to, statements related to (i) expectations regarding the clinical activity profile and potential advantages of the Company's clinical programs, (ii) the timing for the development of a joint Amgen/Company publication strategy for the Phase 1/2 IDE397 and AMG 193 combination, (iii) the timing of preclinical stage MTAP-deletion programs in combination with IDE397 and (iv) nomination of an IDE397 combination development candidate in the second half of 2024. Such forward-looking statements involve substantial risks and uncertainties that could cause actual events and results to differ from those expressed in these forward-looking statements, including those related to the Company's preclinical and clinical development programs. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including the Company's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, serious adverse events, undesirable side effects or unexpected characteristics of drug development programs, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the Company's ability to successfully establish, protect and defend its intellectual property, the sufficiency of existing cash to fund operations, and other matters that could affect the company's business, financial condition, results of operations and prospects. The Company undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual events and results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the Company's Annual Report on Form 10-K filed on February 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEAYA BIOSCIENCES, INC. Date: July 8, 2024 By: /s/ Yujiro Hata Yujiro Hata President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR